REVIEW PAPER
Evaluating the appropriateness of dosing adjustments in the coadministration of maraviroc and CYP3A inhibitors: A literature review
Online publication date: 2016-11-15
HIV & AIDS Review 2016;15(3):122-126
KEYWORDS
ABSTRACT
Aim: To elucidate the appropriateness of once-daily dosing of maraviroc when administered concomitantly with a CYP3A inhibitor, a deviation from the labeled dosing in the United States.
Background: Practitioners have been known to prescribe doses of 300 mg once daily without clear evidence to improve compliance, primarily in patients with medication adherence issues.
Materials and Methods: A review of published literature related to maraviroc pharmacokinetics and pharmacodynamics was performed and data from existing studies is presented and critically evaluated.
Results: The findings with regards to extended dosing intervals of maraviroc in the agent’s pivotal studies are discordant. While the MOTIVATE trials have suggested that the use of MVC once daily is more effective than placebo at reducing HIV-1 RNA levels as well as improving CD4 cell count, the data suggesting this efficacy was determined in studies that had significant limitations, the most important of these limitations being the fact that all patients in the MOTIVATE trials were controlled on optimized background therapy consisting of three to six active antiretroviral agents. MERIT shows that once daily dosing is inadequate due to a lack of viral load suppression.
Conclusion: The use of an extended (once-daily) dosing interval is not supported by current data and such an adjustment may lead to poor viral suppression and potential treatment failure.
Background: Practitioners have been known to prescribe doses of 300 mg once daily without clear evidence to improve compliance, primarily in patients with medication adherence issues.
Materials and Methods: A review of published literature related to maraviroc pharmacokinetics and pharmacodynamics was performed and data from existing studies is presented and critically evaluated.
Results: The findings with regards to extended dosing intervals of maraviroc in the agent’s pivotal studies are discordant. While the MOTIVATE trials have suggested that the use of MVC once daily is more effective than placebo at reducing HIV-1 RNA levels as well as improving CD4 cell count, the data suggesting this efficacy was determined in studies that had significant limitations, the most important of these limitations being the fact that all patients in the MOTIVATE trials were controlled on optimized background therapy consisting of three to six active antiretroviral agents. MERIT shows that once daily dosing is inadequate due to a lack of viral load suppression.
Conclusion: The use of an extended (once-daily) dosing interval is not supported by current data and such an adjustment may lead to poor viral suppression and potential treatment failure.
| eISSN: | 1732-2707 |
| ISSN: | 1730-1270 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
